Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 3
2023 pubmed 12 citations

Protective effects of chronic humanin treatment in mice with diabetic encephalopathy: A focus on oxidative stress, inflammation, and apoptosis.

Bulut. Ferah F; Adam. Muhammed M; Özgen. Aslışah A; Hekim. Munevver Gizem MG; Ozcan. Sibel S; Canpolat. Sinan S; Ozcan. Mete M

Key Findings

  • Humanin (4 mg/kg daily) lowered blood glucose in diabetic mice
  • It reduced oxidative stress and pro‑inflammatory cytokines in the prefrontal cortex and hippocampus
  • It decreased markers of apoptosis, suggesting protection against brain cell loss

Practical Outcomes

  • Humanin shows promise as a neuro‑protective agent for diabetes‑related cognitive decline, but the study is in mice and the human dose is unknown. Biohackers should view this as early‑stage evidence and wait for human trials before adding it to protocols, though it may justify monitoring emerging research on humanin supplements.

Summary

In mice with diabetes, giving the peptide humanin every day for two weeks lowered blood sugar and reduced brain damage signals like oxidative stress, inflammation, and cell death, which together improve memory and thinking abilities.

Abstract

Diabetes is known to cause cognitive impairments through various mechanisms, including oxidative stress, inflammation, and apoptosis. Humanin (HN) has been shown to have protective effects on cognitive impairments induced by factors such as Aβ, muscarinic receptor antagonists, and aging in rodents. However, the mechanisms underlying the protective effects of HN in the prefrontal cortex and hippocampus in the context of diabetes are not well understood. In this study, we aimed to investigate the potential protective role of HN on oxidative stress, inflammation, and apoptosis in mice with diabetes. We divided the mice into four groups, including a control group (treated with saline), a humanin group (treated with 4 mg/kg of HN), a streptozotocin (STZ) group (diabetic control), and an STZ+Humanin group. The mice were administered HN daily for 15 days. Our results showed that in the prefrontal cortex and hippocampus of the diabetes group, oxidative stress parameters, pro-inflammatory cytokines, apoptosis and, blood glucose levels were increased, while antioxidant and anti-inflammatory cytokines were diminished compared to the control group. However, HN treatment was able to modulate these markers, including blood glucose and the markers of oxidative stress, inflammation, and apoptosis. In conclusion, our findings suggest that hyperglycemia, oxidative stress, inflammation, and apoptosis may contribute to the development of diabetes-induced cognitive impairments. By regulating these changes with HN treatment, we may be able to positively contribute to the treatment of cognitive impairments induced by diabetes.

Study Information

Provider

pubmed

Year

2023

Date

2023-07-17T00:00:00.000Z

DOI

10.1016/j.bbr.2023.114584

Citations

12

References

53